Article
Medicine, General & Internal
Eftychia Chatziioannou, Jana Rossner, Thazin New Aung, David L. Rimm, Heike Niessner, Ulrike Keim, Lina Maria Serna-Higuita, Irina Bonzheim, Luis Kuhn Cuellar, Dana Westphal, Julian Steininger, Friedegund Meier, Oltin Tiberiu Pop, Stephan Forchhammer, Lukas Flatz, Thomas Eigentler, Claus Garbe, Martin Roecken, Teresa Amaral, Tobias Sinnberga
Summary: This study aims to evaluate the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in cutaneous melanoma. The analysis of 321 primary tumors and 191 metastatic samples showed that low eTILs were closely associated with unfavorable prognosis. In therapy-naive metastases, high eTILs were associated with better survival outcomes in patients receiving anti-PD-1 immunotherapy.
Article
Oncology
Diego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, Murat Ak, Feliciano Barron, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara-Mejia, Christine B. Peterson, Mehmet E. Er, Vishal Peddagangireddy, Francesco Buemi, Brandon Cooper, Paolo Manca, Rena G. Lapidus, Ru-Ching Hsia, Andres F. Cardona, Aung Naing, Sunjay Kaushal, Fred R. Hirsch, Philip C. Mack, Maria Jose Serrano, Vincenzo Adamo, Rivka R. Colen, Christian Rolfo
Summary: This study evaluated the use of extracellular vesicle PD-L1 expression as a biomarker for predicting durable treatment response and survival in non-small cell lung cancer (NSCLC) patients receiving immune-checkpoint inhibitors (ICIs). The results showed that an increase in extracellular vesicle PD-L1 was observed in non-responders compared to responders and was an independent biomarker for shorter progression-free survival and overall survival. In contrast, tissue PD-L1 expression, the commonly used biomarker, was not predictive for durable response or survival.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Immunology
Lei Wang, Hongbing Zhang, Chaohu Pan, Jian Yi, Xiaoli Cui, Na Li, Jiaqian Wang, Zhibo Gao, Dongfang Wu, Jun Chen, Jizong Jiang, Qian Chu
Summary: A comprehensive predictive model is urgently needed to predict the response to immune checkpoint inhibitors (ICIs) in cancer patients. By studying 162 non-small-cell lung cancer (NSCLC) patients, three genomic biomarkers were identified and used to construct a durable clinical benefit (DCB) prediction model, which showed good predictive value.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Mengke Niu, Ming Yi, Ning Li, Suxia Luo, Kongming Wu
Summary: Immunotherapy, particularly anti-PD-1/PD-L1 treatment, has shown significant improvements in the survival of NSCLC patients, although the overall response rate remains suboptimal. Various factors influence treatment outcomes, indicating the importance of exploring biomarkers to better select patients and predict treatment efficacy accurately.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Yi Liu, Brian Debo, Mingfeng Li, Zhennan Shi, Wanqiang Sheng, Yang Shi
Summary: Targeting the histone demethylase LSD1 can increase the persistence of exhausted CD8(+) T cells in chronic infections and cancer, improving response to immune checkpoint blockade therapy. This strategy may alleviate T cell exhaustion and enhance the effectiveness of immunotherapy.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Yael Haberman, Iris Kamer, Amnon Amir, Sapir Goldenberg, Gilat Efroni, Inbal Daniel-Meshulam, Anastasiya Lobachov, Sameh Daher, Rotem Hadar, Hadas Gantz-Sorotsky, Damien Urban, Tzipi Braun, Jair Bar
Summary: This study aimed to identify a microbial signature associated with lung cancer (LC) diagnosis and to define specific taxa linked with durable clinical benefit (DCB) in advanced LC patients. Stool samples and clinical data were collected from 75 LC patients, including 50 who received checkpoint inhibitors, and 31 healthy volunteers. Comparisons were made between LC patients and healthy controls, as well as between patients with and without DCB. The findings suggest that LC patients have lower diversity and higher variation in their gut microbiome compared to controls. Specific taxa, such as Clostridiales, Lachnospiraceae, and Faecalibacterium prausnitzii, were found to be decreased in LC patients compared to controls. Additionally, high abundance of Akkermansia muciniphila was associated with DCB, suggesting its potential as a biomarker. High abundance of Alistipes onderdonkii and Ruminococcus were also correlated with DCB. These findings highlight the importance of the gut microbiome in LC and suggest potential biomarkers or therapeutic targets for future interventions.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Javier Ros, Iosune Baraibar, Nadia Saoudi, Marta Rodriguez, Francesc Salva, Josep Tabernero, Elena Elez
Summary: Immunotherapy has changed the prognosis of various tumor types, but only tumors with specific genetic features benefit from immune checkpoint inhibitors in metastatic colorectal cancer. Therefore, it is crucial to identify accurate biomarkers to select patients who will respond to treatment and to develop alternative therapies for those who do not respond.
Article
Oncology
Kathleen M. Mahoney, Petra Ross-Macdonald, Long Yuan, Linan Song, Eliseo Veras, Megan Wind-Rotolo, David F. McDermott, F. Stephen Hodi, Toni K. Choueiri, Gordon J. Freeman
Summary: This study investigated the levels of soluble PD-L1 (sPD-L1) before and during nivolumab treatment in metastatic clear cell renal cell carcinoma (RCC) and melanoma patients. The results showed that sPD-L1 levels were associated with worse prognosis and clinical factors. Additionally, changes in sPD-L1 levels during treatment were linked to treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
G. J. Julia Huisman, Nora A. Spraakman, Jeroen V. Koomen, A. Marrit Talsma, Robert A. Pol, Stefan P. Berger, Henri G. D. Leuvenink, Michel M. R. F. Struys, Gertrude J. Nieuwenhuijs-Moeke
Summary: Early non-invasive detection and prediction of graft function after kidney transplantation is important. The study analyzed four urinary biomarkers and found that KIM-1 and NAG at early timepoints after transplantation were significant predictors for eGFR, while NGAL and NAG at day 1 after transplantation were negative predictors. Including these biomarkers improved the prediction models for graft outcome. Factors such as timing of measurement and transplantation factors need to be considered when using urinary biomarkers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Tian Zhang, Patrick M. Forde, Ryan J. Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S. Hurlbert, Mark Stewart, Michael B. Atkins
Summary: With the increasing use of PD-(L)1 inhibitors in different treatment settings, there is a significant need to overcome resistance and provide clinical benefits for patients. This manuscript presents key discussion themes and positions reached through a year-long effort, focusing on eligibility criteria, comparators, endpoints, and trial design options for combination therapies in melanoma, NSCLC, or RCC patients after PD-(L)1 pathway blockade.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Nan Chen, Nicole Higashiyama, Valentina Hoyos
Summary: Immune checkpoint inhibitors are utilized in various malignancies, with challenges remaining in identifying predictive biomarkers in breast cancer. Further research is needed on multiple biomarkers, including tumor mutational burden and genetic alterations in tumor cells, in order to determine the most suitable patient population for ICI therapy.
Article
Oncology
WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo
Summary: In this study, we found that standard blood analytes had prognostic utility, while tumor PD-L1 and tumor mutational burden (TMB) could predict the response of non-small cell lung cancer patients to immune checkpoint inhibitors. Patients with high TMB and high PD-L1 expression showed durable response to immune checkpoint inhibitors. Non-squamous histology, smoking history, and prior chemotherapy enhanced the predictive effect of PD-L1.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Lucile Pabst, Sebastien Lopes, Basil Bertrand, Quentin Creusot, Maria Kotovskaya, Erwan Pencreach, Michele Beau-Faller, Celine Mascaux
Summary: The therapeutic algorithm for lung cancer has been revolutionized by immune checkpoint inhibitors, but the response rate and adverse events remain a challenge. Predictive and prognostic biomarkers are needed to select patients who will respond to treatment. Currently, PD-L1 expression is the only validated biomarker, but its predictive value is imperfect. New molecular features, such as tumor mutational burden, have shown promise in predicting response to immunotherapy. This review summarizes the latest knowledge on predictive and prognostic biomarkers to advance precision immuno-oncology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Benjamin Shum, James Larkin, Samra Turajlic
Summary: Immune checkpoint inhibitors have transformed cancer treatment but many patients still do not benefit. Investigating biomarkers of resistance and response, particularly in host and tumor genomics, can lead to the discovery of new therapeutic targets and personalized treatment strategies. Multivariate multiomic markers may provide a more accurate assessment of response prediction.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Lin Shi, Jinying Lu, Da Zhong, Meijuan Song, Jian Liu, Wenhua You, Wen-Hui Li, Lin Lin, Dongyan Shi, Yun Chen
Summary: Mucosal-associated invariant T (MAIT) cells in non-small cell lung cancer (NSCLC) patients exhibit an exhausted tumor-promoting phenotype and the subset of circulating MAIT cells can predict the response to anti-PD-1 immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
